MAD2L2 and neoplasm: To determine whether REV7 contributes to 5-Fu resistance in vivo, we used HT29 5-Fu-R and HT29 5-Fu-R-KO xenograft to evaluate tumor-suppressive synergy between REV7 deficiency and 5-Fu.